Point72 Asset Management
DNA icon

Point72 Asset Management’s Ginkgo Bioworks DNA Stock Holding History

Point72 Asset Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-76,908
Closed -$639K – 3932
2025
Q4 		$639K Buy
+76,908
New +$828K ﹤0.01% 3117
2025
Q2 		– Sell
-73,100
Closed -$417K – 2288
2025
Q1 		$417K Sell
73,100
-26,700
-27% -$272K ﹤0.01% 1675
2024
Q4 		$980K Buy
+99,800
New +$855K ﹤0.01% 1462

Other funds holding DNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Point72 Asset Management's DNA Position: Q1 2026 in Review

Point72 Asset Management sold out of Ginkgo Bioworks (DNA) in Q1 2026, closing a stake of 76,908 shares — an estimated $639K sold.

Point72 Asset Management first reported a position in DNA in Q4 2024 and held it in 3 quarters. The position peaked at $980K in Q4 2024. 175 funds tracked by Wall St. Rank hold DNA as of Q1 2026.

  • Point72 Asset Management reported no remaining Ginkgo Bioworks position as of Q1 2026 after selling out during the quarter.
  • Point72 Asset Management sold 76,908 Ginkgo Bioworks shares in Q1 2026, an estimated $639K.
  • Point72 Asset Management first reported a position in Ginkgo Bioworks in Q4 2024 and held it in 3 quarters.
  • Point72 Asset Management's Ginkgo Bioworks position peaked at $980K in Q4 2024.
  • 175 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.